A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the efficacy and safety of Generic Escitalopram in the treatment of Chinese patients with depression compared with Innovator Escitalopram(Lexapro®) by evaluating the change of HAMD-17 total score from the baseline to week 8.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Mental Health Center
• Collaborator: Jiangsu Nhwa Pharmaceutical Co., Ltd.
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Outpatients

• Patients who met DSM-IV criteria for major depressive disorder(MDD):a single major depressive episode or recurrent major depressive episode, without psychotic features, MDD is primary mental disorder

• Age from 18-65 years old, male or female

• HAMD-17 total score at least 20 at screening and baseline, and first item's score at least 2

• CGI-S at least 4 at screening and baseline

• Written informed consent provided by patient himself/herself

Exclusion Criteria:

• Severe suicide attempt

• Any unstable medical illness would affect study or increase patients' risk to participate this study, including disease of heart, lung, liver, kidney,cardiovascular system, eyes, nervous system, endocrine system, hematological system etc.

• History of epilepsy(except children febrile seizure/convulsion)

• Known history of high intraocular pressure or angle closure glaucoma

• Psychoactive substance abuse or dependence within 1 year prior enrollment

• Depressive episode due to other mental disorders or physical diseases

• Bipolar disorder, rapid cycling/circulation

• Female patients during their pregnant and lactation period or childbearing potential during study

• History of severe drug hypersensitivity

• A significantly clinical abnormal value in ECG or lab results which would affect assessment for efficacy or safety decided by the investigator

• ALT and AST values in the liver function test exceeding two times of the upper limits of normal values

• Participation in another drug trial within 28 days prior enrollment into this study

• Use of MAOI within 4 weeks prior to randomization

• Duration of discontinuing other psychotropics is shorter than its 7 half life periods

• Patients can not administrate drug according to medical order

• HAMD total score decreased more than 25% from screening to baseline

• Use of Electroconvulsive therapy within half year prior enrollment

• Known lack of efficacy to escitalpram by formal treatment before

• Other situation unsuitable to enroll in this study as judged by the investigator